Chiara Galimberti


I was born in Milan on October the 11th, 1985. I obtained the Bachelor’s Degree in Biotechnology in 2007 and the Master’s Degree in Medical Biotechnology in 2009, both at the University of Milano-Bicocca. I completed the studies for the Master’s degree thesis in Rottapharm Biotech S.r.l. laboratories (molecular biology and biochemical labs), where I worked on the production and characterization of complex proteolytic enzymes involved in Osteoarthrosis (OA). 

Since November 2018 I have been enrolled as a PhD student in Experimental Neuroscience at the University of Milano-Bicocca, School of Medicine and Surgery. My research project is carried out in collaboration with the Rottapharm Biotech S.r.l company and is focused on the study of glioblastoma brain tumour, with the aim of exploring the potential of a new small molecule discovered at Rottapharm Biotech S.r.l for glioblastoma treatment.


Characterization of a novel tyrosine kinase inhibitor in experimental models of glioblastoma.

  • Track: Experimental Neuroscience
  • Tutor: Gianfranco Caselli

Glioblastoma multiforme (GBM) is the most malignant type of primary brain cancer with dismal prognosis and poor survival rate. To date, glioblastoma is not curable; the approved treatment options are limited and palliative and include surgery, adjuvant radiotherapy and chemotherapy with the alkylating agent temozolomide. Glioblastoma is characterized by prominent proliferation, active invasiveness and rich angiogenesis. Although the aetiology has not been yet clearly understood, it is well known that the pathology evolves through different pathways, many of which depend upon the activity of receptor tyrosine kinases (RTKs). Thus, RTKs and their ligands are promising therapeutic targets for the treatment of GBM. In recent years, major clinical trials for small molecule treatment of GBM have failed because the compounds did not reach effective concentrations in the brain; therefore, valid target selection, permeability, and drug pharmacokinetics are important considerations in GBM drug design.

The purpose of this project is to characterize the activity of a novel tyrosine kinase inhibitor in in-vitro and in-vivo experimental models of glioblastoma multiforme (GBM), with the aim of defining its potential for GBM therapy. The project is carried out mostly at Rottapharm Biotech S.r.l. laboratories.


  • Caprioli G, Mammoli V, Ricciutelli M, Sagratini G, Ubaldi M, Domi E, Mennuni L, Sabatini C, Galimberti C, Ferrari F, Milia C, Comi E, Lanza M, Giannella M, Pigini M, Del Bello F. Biological profile and bioavailability of imidazoline compounds on morphine tolerance modulation. Eur J Pharmacol. 2015 Dec 15;769:219-24. doi: 10.1016/j.ejphar.2015.11.021. Epub 2015 Nov 24. PubMed PMID: 26593429.
  • Paolino M, Mennuni L, Giuliani G, Anzini M, Lanza M, Caselli G, Galimberti C, Menziani MC, Donati A, Cappelli A. Dendrimeric tetravalent ligands for the serotonin-gated ion channel. Chem Commun (Camb). 2014 Aug 11;50(62):8582-5. doi: 10.1039/c4cc02502d. Epub 2014 Jun 23. PubMed PMID: 24956157.
  • Chiusaroli R, Visentini M, Galimberti C, Casseler C, Mennuni L, Covaceuszach S, Lanza M, Ugolini G, Caselli G, Rovati LC, Visintin M. Targeting of ADAMTS5’s ancillary domain with the recombinant mAb CRB0017 ameliorates disease progression in a spontaneous murine model of osteoarthritis. Osteoarthritis Cartilage. 2013 Nov;21(11):1807-10. doi: 10.1016/j.joca.2013.08.015. Epub 2013 Aug 15. PubMed PMID: 23954517.

Congress attendance

– EANO (European Association of Neuro-Oncology), Lyon, France, 19-2 September 2019

– AACR (American Association for Cancer Research), Virtual session II: 22-24 June 2020


To get further details and the full pub list, visit: